Pubectomy and Urinary Reconstruction Provides Definitive Treatment of Urosymphyseal Fistula Following Prostate Cancer Treatment
Uro-Oncology
Related content
Erectile and Sexual Functions and DysfunctionsUrinary IncontinenceUro-Oncology
Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade
Cancer Med.
Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL
doi: 10.1002/cam4.1103.
Uro-Oncology
Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer
Prostate Cancer Prostatic Dis.
Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY
doi: 10.1038/pcan.2016.58.
Uro-Oncology
Risk of dementia following androgen deprivation therapy for treatment of prostate cancer
Prostate Cancer Prostatic Dis.
Krasnova A, Epstein M, Marchese M, Dickerman BA, Cole AP, Lipsitz SR, Nguyen PL, Kibel AS, Choueiri TK, Basaria S, Mucci LA, Sun M, Trinh QD
doi: 10.1038/s41391-019-0189-3.
Uro-Oncology
Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease
Prostate Cancer Prostatic Dis.
Sarkar RR, Patel SH, Parsons JK, Deka R, Kumar A, Einck JP, Mundt AJ, Kader AK, Kane CJ, Riviere P, McKay R, Murphy JD, Rose BS
doi: 10.1038/s41391-020-0241-3.
COMMENTED
Uro-Oncology
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.012.
Uro-Oncology
Worse urinary, sexual, and bowel function cause emotional distress and vice versa in men treated for prostate cancer
J Urol.
Orom H, Biddle C, Underwood W 3rd, Nelson CJ
doi: 10.1016/j.juro.2017.12.047.
Uro-Oncology
Complications, oncological and functional outcomes of salvage treatment options following focal therapy for localized prostate cancer: a systematic review and a comprehensive narrative review
World J Urol.
Marra G, Gontero P, Walz JC, Sivaraman A, Tourinho-Barbosa R, Cathelineau X, Sanchez-Salas R
doi: 10.1007/s00345-
Uro-Oncology
EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
Eur Urol.
Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, Bjartell A, Bossi A, Briers E, Briganti A, Buddingh KT, Catto JWF, Colecchia M, Cox BW, Cumberbatch MG, Davies J, Davis NF, De Santis M, Dell'Oglio P, Deschamps A, Donaldson JF, Egawa S, Fankhauser CD, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet JP, Henry AM, Ingels A, Irani J, Lardas M, Liew M, Lin DW, Moris L, Omar MI, Pang KH, Paterson CC, Renard-Penna R, Ribal MJ, Roobol MJ, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots IG, Sedelaar JPM, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, van Leenders GJLH, Varma M, Violette PD, Wallis CJD, Wiegel T, Wilkinson K, Zattoni F, N'Dow JMO, Van Poppel H, Cornford P, Mottet N
doi: 10.1016/j.eururo.2019.09.020.
Benign Prostatic Hyperplasia (BPH)HypogonadismLower Urinary Tract SymptomsUro-Oncology
Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men
BJU Int.
Debruyne FM, Behre HM, Roehrborn CG, Maggi M, Wu FC, Schröder FH, Jones TH, Porst H, Hackett G, Wheaton OA, Martin-Morales A, Meuleman E, Cunningham GR, Divan HA, Rosen RC; RHYME Investigators
doi: 10.1111/bju.13578.